Study type

Study topic

Disease /health condition

Study type

Non-interventional study

Scope of the study

Drug utilisation
Effectiveness study (incl. comparative)
Safety study (incl. comparative)

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Name of medicine, other

Beta-blockers (metoprolol, bisoprolol, carvedilol)

Study drug International non-proprietary name (INN) or common name

METOPROLOL

Anatomical Therapeutic Chemical (ATC) code

(C07) BETA BLOCKING AGENTS
BETA BLOCKING AGENTS

Medical condition to be studied

Chronic obstructive pulmonary disease
Heart failure with reduced ejection fraction
Population studied

Short description of the study population

Patients with heart failure with reduced ejection fraction (HFrEF) and concomitant chronic obstructive pulmonary disease (COPD) registered in the Swedish Heart Failure Registry

Age groups

Adult and elderly population (≥18 years)
Study design details

Study design

Retrospective cohort study using data from the Swedish Heart Failure Registry and other national registers

Main study objective

To assess cardiovascular effectiveness and respiratory safety of beta-blocker treatment in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease

Setting

Patients with HFrEF and concomitant COPD registered in the Swedish Heart Failure Registry between July 2006 and December 2023 are included.

Comparators

Beta-blocker therapy vs no beta-blocker therapy

Outcomes

Primary safety outcome: total number of severe COPD exacerbations (5-years follow-up)
Primary effectiveness outcome: cardiovascular death and total number of heart failure hospitalisations (5-years follow-up)